Amgen Inc. (NASDAQ:AMGN) is a leading biotechnology company known for its innovative therapies and treatments. On February 12, 2025, UBS maintained its "Hold" rating for Amgen, with the stock priced at $295.06. This decision comes amidst Amgen's active participation in industry events, such as the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
At the conference, Amgen was represented by key figures like Narimon Honarpour, Senior Vice President of Global Development, and Justin Claeys, Head of Investor Relations. The event, moderated by Oppenheimer's biotech analyst Jay Olson, allowed Amgen to discuss its strategies and developments in the healthcare sector. This engagement highlights Amgen's commitment to maintaining transparency and communication with investors.
Amgen's stock price of $295.06 reflects a slight decrease of 0.54%, or $1.60, from previous levels. Throughout the trading day, the stock fluctuated between $292.63 and $296.20. Over the past year, Amgen's stock has seen a high of $346.85 and a low of $253.30, indicating some volatility in its market performance.
With a market capitalization of approximately $158.6 billion, Amgen remains a significant player in the biotechnology industry. The company's stock is actively traded, with a current volume of 2,389,926 shares. This level of trading activity suggests continued investor interest and engagement with Amgen's market performance.
